G. Long, AU
Melanoma drug shrinks brain metastases in Phase-I/II study (embargo: 10 October, 11:00 Milan time)
A new drug being developed to treat potentially deadly melanoma skin cancers has shown a promising ability to shrink secondary tumors, known as metastases, in the brain in patients with advanced forms of the disease.
A. Palumbo, IT
High response rate seen in Phase-III trial of chemotherapy, new drug and stem cells in myeloma (embargo: 10 October, 12:30 Milan time)
The first study of its kind comparing two different approaches to treating newly diagnosed multiple myeloma has found that both treatments achieved a positive response.
M. Clavarezza, IT
Most Italian breast cancer patients older, and diagnosed very early (embargo: 10 October, 12:30 Milan time)
A study of breast cancer in Italian women has found that more than 70% of those affected by the disease are over the age of 50 years, and the disease is identified before it has spread to the lymph nodes in more than 60% of cases.
H.A. Azim, BE
Study finds breast-feeding safe for women after breast cancer treatment (embargo: 10 October, 12:30 Milan time)
Women who have survived breast cancer should not be denied the opportunity to breast-feed their children. There is no evidence that breastfeeding is dangerous for mother or child after breast cancer treatment.
K.M. Tveit, NO
Cetuximab adds no benefit to chemotherapy in first-line treatment of metastatic colorectal cancer - New Phase-III data (embargo: 10 October, 13:30 Milan time)
Adding the targeted drug cetuximab to a three-drug chemotherapy regimen for first-line treatment of metastatic colorectal cancer does not improve response rate, progression-free survival or overall survival.
A. Gennari, IT
Prolonging first-line chemotherapy improves outcomes for patien
|SOURCE European Society for Medical Oncology (ESMO)|
Copyright©2010 PR Newswire.
All rights reserved